Todos Medical Ltd [OTCQB: TOMDF] gained 43.88% to $ 0.0400 at the previous close. The total volume of TOMDF stock recorded 50.02M, compared to the 30-day average volume of 7.09M. In the last 52 weeks, TOMDF stock value ranged between $0.0160 and $0.01010. TOMDF stock increased following a validated study data.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Which TOMDF study showed positive results?
As a diagnostic solutions company based in Rehovot, Israel and having office in New York City, Todos Medical develops life-saving diagnostic solutions for detecting cancer before it’s too late. In 2020, TOMDF acquired U.S.-based Provista Diagnostics, Inc. to gain access to its top Alpharetta, Georgia-based CLIA/CAP laboratory for performing PCR COVID testing, as well as its proprietary Videssa breast cancer blood test.
The Todos Biochemical Infrared Analyses (TBIA) tests the immune system for biochemical changes in blood mononuclear cells and plasma, which enables TMDFF to develop its state-of-the-art cancer-screening technology. A number of TOMDF’s cancer-screening tests have received CE marks in Europe, including TMB-1 and TMB-2. The mission of TOMDF is to bring Videssa to market and, subsequently, TBIA.
Earlier this month, Todos Medical and NLC Pharma, its joint venture partner, announced positive validation data for TolloTest, an assay for 3CL proteases. A clinical study evaluated the sensitivity of the test compared to PCR in patients hospitalized for medical conditions unrelated to COVID-19, patients in the hospital for conditions unrelated to COVID-19, and healthy individuals exposed to confirmed COVID-19 cases in the community.
- Positive results were confirmed in both the hospital and outpatient setting with the 3CL protease biomarker compared to the SARS-CoV-2 PCR.
- As a result of the findings, a key role that 3CL protease biomarkers might play in assessing the infectivity status of infected patients released from quarantine and opening a diagnostic window for early diagnosis of individuals with time of time of exposure known has been revealed.
- In addition to both PCR testing and antigen testing for SARS-CoV-2, TOMDF believes the 3CL protease biomarker has a variety of use cases.
- Coronaviruses produce the 3CL protease as their primary protease.
- The 3CL protease is one of the first components of a virus that is made when a cell becomes infected.
- A 3CL protease enzyme is responsible for cleaving coronavirus polypeptides into viral proteins.
- Human bodies do not contain any traces of 3CL protease, so this biomarker will only appear in an active infection.
- Providing users with a 3CL protease test could enable patient identification and assist them to reduce the spread of disease in the event of a pandemic.
TOMDF’s view of 3CL:
Todos Medical (TOMDF) believes that 3CL protease has the potential to become a very important biomarker in the overall diagnostic landscape for COVID-19. So far, the only thing that PCR and antigen testing can determine is whether or not a person has some fragments of the SARS-CoV-2 virus in their system, not if they are replicating the virus and spreading it to others. In addition, the 3CL protease biomarker assay may open up more diagnostic options by indicating SARS-CoV-2 presence more accurately (or when a person no longer becomes infectious after diagnosis) than standards of mandatory 7-, 10-, or 14-day quarantine.
